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Certain bacteria use a type III secretion system (TTSS) to deliver effector proteins that interfere with cell 
function into host cells. While transcription of genes encoding TTSS components has been demonstrated, 
studies to date have failed to identify TTSS effector proteins in Bordetella pertussis. Here we present the first 
evidence of a functionally active TTSS in B. pertussis. Three known TTSS effectors, Bsp22, BopN, and BopD, 
were identified as TTSS substrates in B. pertussis 12743. We found expression of Bsp22 in a significant 
proportion of clinical isolates but not in common laboratory-adapted strains of B. pertussis. We generated a 
TTSS mutant of B. pertussis 12743 and showed that it induced significantly lower respiratory tract colonization 
in mice than the wild-type bacteria. Respiratory infection of mice with the mutant bacteria induced signifi­
cantly greater innate proinflammatory cytokine production in the lungs soon after challenge, and this corre­
lated with significantly higher antigen-specific interleukin-17, gamma interferon, and immunoglobulin G 
responses later in infection. Our findings suggest that the TTSS subverts innate and adaptive immune 
responses during infection of the lungs and may be a functionally important virulence factor for B. pertussis 
infection of humans.
Bordetella pertussis is the causative agent of whooping cough 
or pertussis, a respiratory disease that is most severe in infants 
and young children. Although vaccination has significantly re­
duced morbidity and mortality, pertussis remains an endemic 
disease and is one of the major causes of vaccine-preventable 
deaths today, with WHO estimates of 45 million cases and 
409,000 deaths each year. In recent years a resurgence of 
pertussis was observed in a number of vaccinated populations 
(6, 29). Furthermore, it has become increasingly clear that 
pertussis is not only a childhood disease but also is highly 
prevalent among adults (21). This has called into question the 
level of protection provided by current pertussis vaccines and 
highlighted the need for a better understanding of the molec­
ular mechanisms underlying the pathogenesis of B. pertussis 
infection.
Bacteria produce a complex array of virulence factors, in­
cluding toxins and adhesins, which facilitate colonization 
and/or suppress immune responses and allow the bacteria to 
establish infection in the host. One of these virulence factors, 
the type III secretion system (TTSS), is a specialized secretory 
apparatus that allows gram-negative bacteria to inject proteins, 
known as effectors, directly into the eukaryotic cell cytosol. In 
laboratory conditions bacteria can be induced to secrete TTSS 
substrates, which include effectors and proteins involved in the 
delivery process, into the extracellular milieu in the absence of 
eukaryotic cells. TTSSs have been shown to be important me­
diators of virulence of a range of animal pathogens, including 
Yersinia spp., Salmonella spp., Shigella spp., Escherichia coli, 
andBordetella bronchiseptica (15, 39). Yuk and colleagues have 
reported that the TTSS of B. bronchiseptica modulates den­
dritic cell (DC) maturation (31, 33), enhancing production of 
the anti-inflammatory cytokine interleukin-10 (IL-10) and pro­
moting bacterial persistence (32).
Despite reports describing transcription of genes encoding 
components of the Bordetella bsc TTSS machinery in B. per­
tussis Tohama I (14, 22), the B. pertussis isolate chosen for 
genome sequencing, studies to date have failed to demonstrate 
TTSS effector secretion by B. pertussis in vitro or in vivo (9, 22). 
The sequencing of the B. pertussis Tohama I genome has re­
vealed an extraordinary high level of genetic flexibility (28), 
and this raises concerns about the adequacy of laboratory- 
adapted strains for the study of natural clinical pathogenesis. 
Differences in gene expression have been shown to affect vir­
ulence characteristics of laboratory-adapted versus corre­
sponding low-passage clinical isolates of E. coli, Staphylococcus 
aureus, and Pseudomonas aeruginosa (11, 34, 37).
Here we demonstrate secretion of the Bordetella TTSS ef­
fector, Bsp22, by a significant portion of low-passage clinical 
isolates of B. pertussis, but not by common laboratory-adapted 
strains, such as Tohama I and Wellcome 28. Mutation of bscN, 
which encodes an essential component for TTSS secretion 
across bacterial membranes, abolished in vitro secretion of 
TTSS substrates by a clinical isolate of B. pertussis, resulting in 
a reduced ability of the bacteria to colonize the respiratory 
tracts of mice, and this was associated with enhanced local 
inflammatory and antigen-specific cellular and humoral im­
mune responses. Our data suggest that expression of a func­
tional TTSS is a feature of natural infection of humans with B. 
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pertussis and that this may confer virulence to the bacteria by 
subverting the protective innate and adaptive immunity of the 
host.
MATERIALS AND METHODS
Bacterial strains and growth media. Low-passage isolates B. pertussis ATCC 
12743 (5375 [3865]), ATCC 12742 (5374 [3747]), and ATCC 9340 (5 [17921]), 
hereafter referred to as B. pertussis 12743, 12742, and 9340, respectively, were 
obtained from the ATCC. B. pertussis 12743 and 12742 were from cultures made 
by E. K. Anderson and deposited in the ATCC by G. Eldering (8), and B. 
pertussis 9340 was from a culture made by P. Kenrick and deposited in the ATCC 
by M. Pittman in the 1950s. Sixteen clinical isolates were cultivated from the 
sputum, noses, nasopharynges, or throats of infants or adults with whooping 
cough in The Netherlands between 1949 and 2005. Wild-type (WT) B. pertussis 
and B. bronchiseptica were grown at 37°C on Bordet-Gengou (BG) agar and in 
Stainer-Scholte (SS) broth. Gentamicin-resistant SbscN derivatives of 5. pertussis 
12743 and B. bronchiseptica RB50 were grown on BG agar or SS broth supple­
mented with 10 pg/ml gentamicin (Gibco, United Kingdom). For allelic 
exchange WT B. pertussis 12743 was first rendered streptomycin resistant by 
subculture in increasing sublethal concentrations of streptomycin (final concen­
tration, 100 pg/ml). For routine cloning and conjugation, E. coli XL'l-Blue and 
SMIOXpir were grown at 37°C on Luria-Bertani (LB) agar or LB broth (BD 
Difco) supplemented with the appropriate antibiotics (ampicillin, 150 pg/ml; 
gentamicin, 10 pg/ml; kanamycin, 25 pg/ml).
Generation of AbscN bacteria. Gentamicin-resistant NbscN derivatives of B. 
pertussis 12743 and B. bronchiseptica RB50, in which a 0.5-kb internal portion of 
the bscN gene was removed and replaced with a 0.7-kb fragment containing a 
gentamicin resistance cassette, were constructed as follows. Primers PAB20 
(5'-GCCCTGCGGATCCCGCG-3T and NF5 (5'-TACTGACGCATGCCCCT 
ATCC-3'), annealing to bp 65 to 81 of bscL (5' flanking gene to bscN) and bp 1 
to 12 of bscN, respectively, were used to amplify a 0.5-kb fragment from Tohama 
I. The resulting PGR product was digested with BamHI and SphI (recognition 
sequences underlined in primer sequences) and inserted into the corresponding 
sites of the cloning vector pQE-80 (Qiagen, United Kingdom) to produce pNF2. 
Primers NF4 ('5'-GCTGGGCATGCTGGTCAAGGGC-3'') and PAB21 (5'-GC 
CGGCTCGCGATGCATCG-3'), annealing to bp 560 to 582 of bscN and bp 470 
to 489 of bscO (3' flanking gene to bscN), respectively, were used to amplify a 
1.3-kb fragment from Tohama I. The resulting PGR product was digested with 
SphI and Agel (recognition sequence underlined in primer sequence) to yield a 
0.5-kb fragment and inserted into the corresponding SphI and Xmal sites on 
pNF2 to create pNF7, containing a mutant bscN allele. The gentamicin resis­
tance cassette was amplified from pSSl'129 using primers Gmr_for_2 (5'-ATA 
GCATGCTGACGCACACCG-3'j and Gmr_rev (5'-GCATGCTTAGGTGGC 
GGTAC-3') with SphI sites engineered at the 5' and 3' ends, respectfully, and 
inserted into the unique SphI site at the center of the mutant bscN allele on 
pNF7 to create pNF'12. BamHI (bp 1 to 6 of the bscNr.Gm1 mutant allele) and 
Nhel (138 bases downstream) sites flanking the bscN::Gmr mutant allele on 
pNF'12 were then used to subclone the bscNt'.Gm1 mutant allele into the allelic 
exchange vector pEGBR (1) to create pNF'13. pNF'13 was then introduced into 
streptomycin-resistant B. pertussis 12743 and B. bronchiseptica RB50 by conju­
gation, and gentamicin-resistant double recombinants of B. pertussis 12743 and 
B. bronchiseptica RB50 generated by allelic exchange were screened by PGR for 
the presence of the bscNv.GvN mutant allele.
Recombinant His-Bsp22 and Ab production. Primers PAB37 f5'-CGGAAG 
CTTTTAGCGCATGTTGCTGGTG-3'), which binds bp 596 to 615 of the 
Bsp22 gene, and PAB38 f5'-AGCGGATCCAGCATTGATCTCGGAGTTCA 
C-3'), which binds bp 4 to 25 of the Bsp22 gene, were used to amplify the Bsp22 
gene from B. pertussis 18323. The resulting PGR fragment was cloned in frame 
with the six-His tag located on pQE-80 (Qiagen, United Kingdom), creating 
pAPB15, from which recombinant His-tagged Bsp22 was expressed in E. coli 
XL'l-Blue. His-Bsp22 was purified by affinity chromatography on Ni2+ columns. 
For antibody (Ab) production, a rabbit was immunized subcutaneously with 
recombinant His-Bsp22 (230 |JLg) emulsified in complete Freund’s adjuvant 
(Difco) and boosted on days 14 and 28 with His-Bsp22 (115 |JLg) in incomplete 
Freund’s adjuvant. The rabbit was exsanguinated 12 days after the last immuni­
zation, and serum was prepared and shown by Western blotting to contain an Ab 
that specifically recognized Bsp22.
Protein identification by MALDI-TOF mass spectrometry and immunoblot­
ting. For matrix-assisted laser desorption-ionization-time of flight (MALDI- 
TOF) mass spectrometry analysis of protein samples, culture supernatants were 
harvested from Bordetella spp. following 24 h of growth in liquid culture. Filtered 
supernatants were precipitated with 30% ammonium chloride. Protein pellets 
were analyzed by MALDI-TOF mass spectrometry, and identified peptide frag­
ments were searched against the predicted proteins from the complete B. bron­
chiseptica RB50 and B. pertussis Tohama I genomes (www.sanger.ac.uk/Projects 
/B_pertussis/). For Western blots, cultures were harvested for each bacterial 
strain at the same stage of bacterial growth, as determined by measurements of 
optical density at 600 nm (OD600), and total protein from a 1-ml supernatant 
fraction was precipitated with 10% (wt/vol) trichloroacetic acid and resuspended 
in sample buffer. Proteins were separated on 10% (wt/vol) sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis gels and transferred to nitrocellulose 
membranes (Sigma) prior to Western blotting with a polyclonal Ab raised against 
B. pertussis Bsp22, pertussis toxin (PT), or filamentous hemagglutinin (FHA), 
followed by the appropriate secondary Ab.
In vitro growth curves. B. pertussis 12743 and NbscN B. pertussis 12743 were 
grown in SS medium in 100-ml cultures inoculated at a starting OD600 of 0.2. 
Samples (1 ml) were removed at 4, 8, 12, 23, 27, 37, and 49 h, OD600 was 
determined, and CFU counts were performed by plating neat and diluted sam­
ples on BG agar plates.
In vitro cytotoxicity and adherence assays. DC were expanded in vitro from 
bone marrow of BALB/c mice by culture for 10 days with granulocyte-macro- 
phage colony-stimulating factor as described previously (13). Murine DC, 1774 
macrophages, and human HEK-293T epithelial cells (1 X 106/ml) were incu­
bated in Dulbecco’s modified Eagle’s medium supplemented with 8% fetal calf 
serum in 24-well plates. Stationary-phase cultures of Bordetella spp. were har­
vested, resuspended in 1% casein, and added to triplicate wells at a multiplicity 
of infection (MOI) of 20,100, or 500. Cytotoxicity was determined after 4 h using 
the Cytotox 96 nonradioactive cytotoxicity assay (Promega), which measures 
lactate dehydrogenase release as a measure of cell lysis. For detection of bacte­
rial adherence to macrophages and of internalization, 1774 cells were incubated 
with Bordetella spp. at an MOI of 100. Following incubation at 37°C for 2 h, the 
contents of each well were harvested, washed to remove unbound bacteria, and 
resuspended in either 1 ml of medium supplemented with kanamycin (100 
pg/ml) to kill extracellular bacteria or 1 ml medium alone. The cell suspensions 
were incubated at 37°C for a further 1 h and then centrifuged at 1,200 rpm for 
5 min. The cells were washed and resuspended in 1 ml phosphate-buffered saline 
with 1% (wt/vol) Triton X-'lOO and left at room temperature for 5 min. One 
hundred-microliter samples of the appropriate dilutions of the lysed cells were 
then plated in triplicate onto BG agar plates and incubated at 37°C for 2 days for 
B. bronchiseptica and 3 to 5 days for B. pertussis.
B. pertussis infection of mice. Mice were infected with WT or NbscNB. pertussis 
12743 by exposure to an aerosol of bacteria for 15 min as described previously 
(20). The standard inoculum was 2 X IO10 bacteria/ml (based on OD600), and this 
was reduced or increased by two- to threefold to achieve a lower or higher initial 
colonization. Four mice from each experimental group were sacrificed 3 h and 3, 
7, 14, 21, and 28 days after challenge to assess the number of viable bacteria in 
the lungs. The numbers of CFU in lung homogenates were estimated as de­
scribed previously (20). Results are given as the mean numbers of B. pertussis 
CFU for individual lungs from four mice per experimental group. The sensitivity 
of the assay was 0.56 log10 CFU per lung.
Quantification of cytokine concentrations and neutrophil infiltration into the 
lungs. Lung homogenates were centrifuged at 13,000 rpm for 5 min, and the 
concentrations of IL-'IO, IL-'12p70, IL-'1£, tumor necrosis factor alpha (TNF-a), 
macrophage inflammatory protein 1 (MIP-1) and MI P-2 (R&D Systems), IL- 
12p40, IL-6, and transforming growth factor 3 (BD Pharmingen) were deter­
mined by enzyme-linked immunosorbent assay (ELISA) according to the man­
ufacturer’s instructions. Neutrophil infiltration into the lungs was quantified by 
performing differential counts on hematoxylin-and-eosin-stained cytospin prep­
arations of cells recovered by bronchoalveolar lavage as described previously 
(23).
Detection of antigen-specific immune responses. Spleens and serum samples 
were recovered from mice 14, 21, and 28 days after bacterial challenge. Spleen 
cells (2 X 106 cells/ml) were stimulated with sonicated B. pertussis, PT, FHA, or 
medium alone and incubated at 37°C for 72 h. Supernatants were removed, and 
gamma interferon (IFN-y) and IL-17 concentrations were determined by 
ELISA. Lung T cells were purified on T-cell isolation columns as described 
previously (23). Lung T cells were stimulated with heat-inactivated B. pertussis 
antigen and splenic antigen-presenting cells (2 X 106 irradiated spleen cells). 
After 5 days the surviving T cells were stimulated with phorbol myristate acetate 
and ionomycin for 1 h, and then brefeldin A was added for 4 h at 37°C. Cells were 
stained with fluorescently labeled Abs specific for CD4 (eBioscinces). Cells were 
then fixed, permeabilized, and incubated with fluorescently labeled anti-IFN-y or 
anti-IL-17 Abs (BD Pharmingen) according to the manufacturer’s instructions 
(Fix & Perm cell permeabilization kit; Invitrogen). Immunofluorescence was 
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analyzed using Summit software on a Cyan ADP flow cytometer (Dako). Anti-5. 
pertussis immunoglobulin G (IgG), IgG2a, and IgG'l Ab titers were determined 
by ELISA as described previously (13). Results are expressed as log10 end point 
Ab titers, determined by extrapolation of the straight part of the dilution curve, 
versus the OD492 value of the control serum for naive mice.
Statistical analysis. Statistical analysis was performed using Graphpad Prism. 
Student’s t test was used to compare the mean values between two groups. 
Statistical differences in mean values between more than two experimental 
groups were determined by analysis of variance. Linear regression was used to 
examine the correlation between bacterial growth estimated by CFU counts and 
OD600. A nonlinear regression analysis was performed on the growth curves for 
B. pertussis 12743 and SbscN B. pertussis 12743. An Akaike’s information crite­
rion test with a confidence interval of 95% was applied to the data, with a 
supplemental t test, to determine if the growth curves of bacterial strains are 
different.
RESULTS
Secretion of TTSS effector proteins by clinical but not lab- 
oratory-adapted isolates of B. pertussis. B. pertussis Tohama I is 
well characterized and was chosen for genome sequencing (28) 
but has been through extensive laboratory passage since its isola­
tion in Japan in 1954 (16). Since the TTSS expression and secre­
tory function of Yersinia is regulated and activated in vivo by 
eukaryotic cell contact and can be altered by prolonged labora­
tory passage (4,36), we examined low-passage B. pertussis isolates 
from the ATCC (B. pertussis 12743, 12742, and 9340) and com­
pared these with the laboratory-adapted strains (Tohama I and 
Wellcome 28) for expression of Bsp22. Bsp22, whose gene is 
located in the TTSS operon in B. pertussis and B. bronchiseptica 
(www.sanger.ac.uk/Projects/Bjaertussis/), is secreted by B. bron­
chiseptica (39) and is a useful marker of TTSS secretory function. 
In the present study, His-tagged Bsp22 was cloned and expressed 
in E. coli and the purified protein was used to generate polyclonal 
anti-Bsp22 Abs. Western blotting with anti-Bsp22 revealed signif­
icant quantities of secreted Bsp22 protein in culture supernatants 
of B. pertussis 12743 and 9340, but not in 12742, Tohama I, or 
Wellcome 28 (Fig. 1A). These data demonstrate that two of the 
three early isolates from the ATCC that were examined expressed 
TTSS proteins in vitro, but this may have been lost in the common 
laboratory-adapted strains Tohama I and Wellcome 28.
We next examined supernatants from stationary-phase cul­
tures of 16 clinical isolates, cultivated from infants or adults 
with whooping cough in The Netherlands between 1949 and 
2005. Western blotting with anti-Bsp22 Abs revealed secretion 
of Bsp22 in 15 of 16 isolates (Fig. 1; results are shown for 8 
clinical isolates; an additional 8 [not shown] all expressed 
Bsp22). Bsp22 was also detected in B. bronchiseptica RB50 but 
not /I pertussis Tohama I or Wellcome 28. PT was detected in 
all strains except B. bronchiseptica RB50, confirming that the 
clinical isolates were B. pertussis and not B. bronchiseptica. 
These results demonstrate that a large proportion of the low- 
passage clinical isolates of B. pertussis examined have a func­
tional TTSS.
In order to confirm these findings and to facilitate identifi­
cation of additional Bordetella TTSS substrates, we carried out 
mass spectroscopy analysis on total secreted proteins from 
culture supernatants. MALDI-TOF analysis revealed a num­
ber of known Bordetella virulence factors, including FHA, 
adenylate cyclase toxin, and pertactin in B. pertussis Tohama I, 
B. pertussis 12743, and B. bronchiseptica RB50 (Table 1), as 
well as other proteins not yet implicated in virulence (data not
A Bp Bp Bp Bp Bp Ilis-
9340 12743 12742 Toh-I W28 Bsp22
Bsp22
B
Bb Bp Bp Bp Bp Bp Bp Bp Bp Bp Bp Bsp22/ 
RB50 W28 Tohl 1868 0640 0335 059 1304 0546 078 2780 PT
Bsp22 ♦ —
PT 
SI
S2/S3
S4/S5
FIG. 1. Clinical isolates but not common laboratory-adapted stains 
of B. pertussis express Bsp22. Protein samples from supernatants of 
stationary-phase cultures of B. pertussis (Bp) 9340, 12743, 12742, To­
hama I (Toh-I), and Wellcome 28 (W28) (A) or B. bronchiseptica (Bb) 
RB50, B. pertussis W28 and Toh-I, and eight clinical isolates of B. 
pertussis recovered from respiratory tracts of patients with whooping 
cough (B), prepared by precipitation with 10% trichloroacetic acid or 
purified His-Bsp22 or PT (2 pg), were resolved on sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis gel and probed with Abs 
specific for Bsp22 or PT (SI to S5 subunits) by Western blotting.
shown). Tracheal colonization factor, a virulence factor of B. 
pertussis but not B. bronchiseptica (10), was detected in B. 
pertussis Tohama I and B. pertussis 12743 but not B. bronchi­
septica RB50. Serum resistance protein (BrkA) was detected in 
B. pertussis Tohama I and B. pertussis 12743 but not B. bron­
chiseptica RB50; BrkA expression has been demonstrated for 
some strains of B. bronchiseptica, but not for strain RB50 (30). 
PT, a B. pertussis-specific virulence factor, was also detected in 
B. pertussis 12743; this required a separate analysis from that 
shown in Table 1, using more concentrated culture supernatant 
(not shown). As well as Bsp22, the TTSS translocator protein, 
BopD, and the sensor/plug protein, BopN, were detected in 
supernatants from B. pertussis 12743 but not B. pertussis To­
hama I. The Bordetella TTSS effector protein, BteA/BopC, was 
detected in B. bronchiseptica RB50 but not in B. pertussis 
12743. These results provide further evidence that B. pertussis 
12743 has a functional TTSS in vitro and demonstrate for the 
first time that BopD and BopN, in addition to Bsp22, are 
substrates of the B. pertussis TTSS.
Mutation of bscN abolishes expression of TTSS effector pro­
teins by B. pertussis 12743 but does not affect bacterial growth 
in vitro. In order to assess the contribution of the TTSS to the 
virulence of BP 12743, we constructed a strain carrying an 
insertional mutation of the bscN gene. Mutation of bscN in B. 
bronchiseptica or its homologs, yscN in Yersinia and invC in 
Salmonella, has been shown to abolish in vitro TTSS secretion 
and in vivo TTSS-mediated effects on host cells (7, 38^-0). For 
comparative purposes, we also mutated bscN in B. bronchisep­
tica RB50. Bsp22 protein was detected by Western blotting in 
the culture supernatants of WT B. pertussis 12743 and B. bron­
chiseptica RB50 but not in MiscN derivatives (Fig. 2). Further-
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TABLE 1. Identification of secreted TTSS substrates and other virulence factors from Bordetella spp. by MALDI-TOF mass spectrometry"
Mascot 
accession no. Identified protein
Result for:
B. pertussis
Toh I
B. pertussis 
12743
AbscN
B. pertussis 
12743
B. bronchiseptica
RB50
AbscN
B. bronchiseptica
RB50
BP1879/BB2993 FHA + (141) + (8,869) + (3,776) + (567) + (434)
BP0760/BB0324 Bifunctional hemolysin-adenylate + (116) + (2,423) + (1,074) + (2,551) + (2,571)
cyclase toxin (CyaA)
BP1054/BB1366 Pertactin (Prn) + (111) + (2,066) + (759) + (450) + (350)
BP3494/BB0961 Serum resistance protein (BrkA) + (234) + (2,261) + (1,893) - -
BP1201 BB3291 Tracheal colonization factor + (412) + (1,530) + (3,117) - -
(TcfA)
BP2256/BB1617 Putative secreted protein - + (470) - + (500) -
(Bsp22)
BP2253/BB1620 Putative outer protein D (BopD) - + (781) - + (193) -
BP2257/BB1616 Putative outer protein N (BopN) - + (204) - - -
BP0500/BB4228 Hypothetical protein - - - + (67) -
(BteA/BopC)
" Quantitative MALDI-TOF tandem mass spectrometry analysis was carried out on extracted proteins from culture supernatant of B. pertussis Tohama I (Toh I). 
B. pertussis 12743, AbscN B. pertussis 12743, B. bronchiseptica RB50, and AbscN B. bronchiseptica RB50. Identified peptides were searched against the complete B. 
bronchiseptica and B. pertussis genome sequences (www.sanger.ac.uk/Projects/B_pertussis/) using the Mascot search engine. Numbers in parentheses represent the 
individual Mascot ion scores. Individual ion scores >33 indicate identity or extensive homology (P < 0.05).
more, Bsp22, BopN, and BopD were detected by mass spec­
trometry analyses of secreted proteins of WT but not AbscN 
derivatives (Table 1). Mutation of bscN did not affect secretion 
of other virulence factors, including FHA, adenylate cyclase 
toxin, and pertactin (Table 1 and Fig. 2). These results dem­
onstrate that mutation of the bscN gene abolishes secretion of 
TTSS substrates by B. pertussis 12743 and B. bronchiseptica 
RB50 and demonstrate that BscN is an essential component of 
the B. pertussis TTSS. Furthermore, mutation of bscN did not 
significantly affect bacterial growth rate. The in vitro growth 
curves based on ODf)00 (Fig. 3A) and CFU (Fig. 3B) were 
almost superimposable for B. pertussis 12743 and AbscN B. 
pertussis 12743. Nonlinear regression analysis with Akaike’s 
information criterion test determined that there was a 93% 
probability that the curves for the two bacterial strains were 
identical. Furthermore linear regression analysis demonstrated 
a highly significant (P < 0.001) correlation between ODf)00 and 
CFU for B. pertussis 12743 and AbscN B. pertussis 12743. These 
findings demonstrate that OD600 can be used as an accurate 
estimate of the number of viable bacteria and suggest that 
equivalent numbers of viable WT and TTSS mutant bacteria 
were employed for experiments to compare the virulence levels 
of and immune responses to B. pertussis 12743 and AbscN B. 
pertussis 12743 in vitro and in vivo.
Bb
RB50
Bb Bp
RB50 12743
AbscN
Bp Bp 
12743 Toh-I
AbscN
FH,\
Bsp22
-
FIG. 2. Mutation of bscN in Bordetella spp. abolishes Bsp22 pro­
duction but does not affect secretion of the virulence factor FHA. 
Proteins from culture supernatants of WT and AbscN B. pertussis (Bp) 
12743 and B. bronchiseptica (Bb) RB50 or B. pertussis Tohama I 
(Toh-I) were examined for the presence of Bsp22 and FHA by West­
ern blotting.
The TTSS of/J. pertussis 12743 promotes adherence to macro­
phages but does not mediate cytotoxicity in vitro. Consistent 
with previous reports (39, 40), B. bronchiseptica RB50 was 
significantly cytotoxic to cultured epithelial cells, macrophages, 
and DC (Fig. 4A) and this activity was lost in the AbscN 
mutant. In contrast, no significant cell lysis was detected in any 
cell type incubated with WT or AbscN B. pertussis 12743. The 
TTSS of Yersinia spp. plays a crucial role in preventing bacte­
rial uptake during infection (4), while the TTSS of Salmonella 
spp. mediates bacterial uptake to facilitate tissue invasion and 
intracellular replication (12). Here we investigated the role of 
the Bordetella TTSS in bacterial uptake. Significantly higher 
CFU were detected in kanamycin-treated macrophages cul­
tured with AbscN B. bronchiseptica than in those cultured with 
WT B. bronchiseptica, indicative of a higher number of inter­
nalized viable mutant bacteria (Fig. 4B). After correcting for 
cell death induced by B. bronschiseptica, there was still signif­
icantly greater uptake of the mutant than the WT B. bronschi­
septica (data not shown). In contrast, the numbers of CFU 
recovered following treatment with medium only were similar 
following culture with WT or AbscN B. bronchiseptica, suggest­
ing that the TTSS of B. bronchiseptica did not facilitate binding 
to the cell surface. The numbers of viable WT and AbscN B. 
pertussis 12743 CFU recovered from kanamycin-treated macro­
phages were very similar, indicative of similar numbers of in­
ternalized B. pertussis CFU. In contrast, the number of viable 
B. pertussis CFU recovered following treatment with medium 
alone from cells cultured with AbscN B. pertussis f2743 was 
significantly lower than the number of WT bacteria, indicating 
a lower number of cell-associated bacteria following incuba­
tion with the mutant bacteria (Fig. 4B). These results demon­
strate that the TTSS of B. bronchiseptica RB50 inhibits bacte­
rial uptake by murine macrophages, whereas the TTSS of B. 
pertussis f2743 promotes adherence of the bacteria to macro­
phages in vitro.
Enhanced innate and adaptive immune responses in mice 
infected with AbscN B. pertussis 12743. Protective immunity to 
B. pertussis involves a combination of local innate inflamma-
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FIG. 3. Correlation between in vitro growth curves for B. pertussis 
(Bp) 12743 and MscN B. pertussis 12743. B. pertussis 12743 and MscN 
B. pertussis 12743 were cultured for 2 days in SS medium, and samples 
were removed at the indicated time points. (A) OD600 was determined. 
(B) The number of viable bacteria was determined by performing CFU 
counts after plating on BG agar. (C) CFU counts were plotted against 
OD600 for each strain separately, and linear regression analysis was 
performed. The correlation (rvalue) and level of significance (P value) 
are shown.
tory responses in the lungs (13, 24) and adaptive immune 
responses, mediated by Thl and Thl7 cells, which help to clear 
bacteria from the respiratory tract (13, 20). Here, we examined 
local innate inflammatory cytokine production in the lungs of 
mice infected with WT and MscN B. pertussis 12743. We de­
tected significantly higher concentrations of the proinflamma- 
tory cytokines, TNF-a (P < 0.01), IL-1[3 (P < 0.01) and IL-6 
(P < 0.05), and proinflammatory chemokines MIP-la (P < 
0.01 ) and MIP-2 (P < 0.05 ) in the lungs 3 h after challenge with 
the MscN bacteria compared with WT B. pertussis 12743 (Fig. 
5). Furthermore, the concentrations of IL-1|3, MI P-1 a, and 
MIP-2 remained significantly higher in the lungs of mice in­
fected with the MscN B. pertussis 12743 up to 7 to 14 days 
postchallenge. We also detected significantly higher concentra­
tions of IL-12p40 and IL-6 in the lungs of mice 7 days after 
challenge with MiscN B. pertussis 12743. In contrast, the con­
centrations of the immunosuppressive cytokine IL-10 were 
consistently lower in mice infected with MiscNB. pertussis than 
in those infected with WT bacteria. The concentration of trans­
forming growth factor |3 in the lungs was not significantly 
changed over the course of infection with B. pertussis 12743 or 
MscN B. pertussis 12743 (Fig. 5). These results suggest a role 
for the TTSS of B. pertussis 12743 in suppressing innate proin­
flammatory cytokine and chemokine responses in the lungs, 
especially early in infection.
Analysis of the cellular content of bronchoalveolar lavage 
samples 7 days postchallenge revealed a nonsignificant in­
crease in the number of neutrophils in the lungs of mice in­
fected with MscN B. pertussis 12743 ( 4.6 x 104 ± 1.5 x 
104/lung) compared with that in lungs of mice infected with B. 
pertussis 12743 ( 2.6 x 104 ± 1.5 x 104/lung). However, histo­
logical analysis of lungs did not reveal evidence of increased 
pathology in the lungs of mice infected with the mutant versus 
WT bacteria (data not shown).
We examined antigen-specific cytokine production in mice 
infected with WT or MscN B. pertussis 12743 by stimulation of 
spleen cells with B. pertussis sonicate, purified PT, or FHA. We 
detected B. pertussis-specific IL-17 and Il N-y production by 
spleen cells recovered 14 or 21 days after infection of mice with 
WTB. pertussis 12743 (Fig. 6). However, antigen-specific IL-17 
and Il N-y production was significantly stronger in mice in­
fected with MscN B. pertussis T21A3. The enhanced IL-17 
production in mice infected with the mutant bacteria in re­
sponse to PT and also to B. pertussis sonicate was particularly 
striking, and this was a consistent finding at days 14, 21 (Fig. 6), 
and 28 (data not shown) postchallenge. Preliminary experi­
ments to determine the frequency of antigen-specific T cells in 
the lungs of infected mice (based on a single time point, day 14 
postchallenge) revealed a higher frequency of B. pertussis-spe­
cific Thl and Thl7 cells in mice infected with MscN B. per­
tussis 12743 (IFN-y secreting, 2.86%; IL-17 secreting, 1.98%) 
than in mice infected with the WT bacteria (IFN-y secreting, 
1.92%; IL-17 secreting, 0.88%). Collectively, these results sug­
gest that the TTSS may suppress antigen-specific IFN-y and 
IL-17 production during infection of mice with B. pertussis 
12743. Significantly higher B. pertussis-specific serum IgG lev­
els in mice infected with MscNB. pertussis 12743 than in mice 
infected with WT bacteria were also observed (Fig. 7). Con­
sistent with the stronger Thl responses, we detected signifi­
cantly higher titers of serum IgG2a in mice infected with MscN 
B. pertussis 12743 (Fig. 7). In contrast, there were no differ­
ences in serum IgGl between the mutant and WT bacteria. 
These results suggest that the Bordetella TTSS may suppress 
Ab responses, especially IgG2a, as a consequence of suppress­
ing the induction of Thl cells.
The TTSS of B. pertussis 12743 enhances bacterial persis­
tence in the lungs of mice. In order to examine the role of a 
functional TTSS in virulence of Bordetella in vivo, BALB/c 
mice were infected by exposure to an aerosol containing equiv­
alent concentrations (2 x 10lo/ml) of either WT or MscN B. 
pertussis 12743. After an initial rise in bacterial numbers, peak­
ing at day 7, WT B. pertussis 12743 began to be steadily cleared 
from the lungs between days 7 and 21, with complete clearance 
of the bacteria 28 days postinfection (Fig. 8A). In contrast, 
MscN B. pertussis 12743 colonized the lungs to a significantly 
lower degree at each time point examined and began to be 
cleared from the lung earlier in infection and was completely
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A Epithelial cells
FIG. 4. The TTSS of B. pertussis 12743 promotes bacterial adherence to macrophages but does not mediate cytotoxicity. (A) Epithelial cells, 
J774 macrophages, or bone marrow-derived DC were cultured with WT or ¿sbscN B. pertussis (Bp) 12743 or B. bronchiseptica (Bb) RB50 at MOIs 
of 20, 100, and 500 for 4 h. Cytotoxicity was measured by a lactate dehydrogenase release assay. (B and C) J774 macrophages were cultured with 
WT or ¿sbscN B. bronchiseptica RB50 (B) or B. pertussis 12743 (C) at an MOI of 100:1. Adherence was assessed by assessing CFU counts following 
2 h of incubation followed by 1 h of treatment with kanamycin or medium only. *, P < 0.05; **, P < 0.01 (AbscN versus WT). Results are 
representative of three experiments.
cleared by day 21. The lower number of mutant bacteria re­
covered 3 h after challenge was a consistent finding in three 
experiments using our standard challenge inoculum. Evidence 
from over 100 challenge experiments with B. pertussis has 
shown that this method of infection results in highly reproduc­
ible lung colonization of mice within an experiment. Further­
more, we have also shown a highly significant correlation be­
tween protection in this model and vaccine efficacy in children 
(26). We used OD600 to estimate the number of bacteria in the 
challenge inoculum, and, since there was a highly significant 
correlation between OD600 and CFU counts (Fig. 3), it is 
unlikely that the difference in colonization at 3 h reflects ex­
posure to a lower number of viable bacteria. Furthermore, the 
in vitro growth curves, as determined by measuring either 
OD600 or CFU, for the TTSS mutant and WT bacteria were 
almost identical (Fig. 3). Nevertheless, in order to provide 
further evidence of the impact of the TTSS on virulence in 
vivo, we examined the course of infection when differing con­
centrations of the challenge inocula resulted in higher or lower 
initial lung colonization. In a challenge experiment where the 
initial colonization was 3.8 log10 CFU per lung for the WT B. 
pertussis, ¿sbscN B. pertussis 12743 was cleared within 7 days 
and there were significantly greater numbers of CFU recov­
ered at 3, 7, and 14 days postchallenge from the lungs of mice 
infected with the WT bacteria than with mutant bacteria (Fig. 
8B). In contrast, when the initial colonization was 4.8 log10 
CFU per lung for the WT B. pertussis, the effect of the muta­
tion was less obvious. Although CFU recovered from the mice 
infected with the TTSS mutant were 4- to 10-fold (0.6 to 1 
log10) lower than CFU of WT B. pertussis on days 3 and 7, 
these differences were not statistically significant (Fig. 8C). 
The absence of the TTSS and the corresponding loss of its cell 
binding and immunosuppressive effects may be less obvious 
when the lungs are overwhelmed with a high number of bac­
teria in the aerosol. Nevertheless the dramatically reduced 
CFU recovered from mice infected with the TTSS mutant in 
mice with lower initial colonization (which may be more rele­
vant to the mode of exposure in humans) suggests that the 
TTSS does play an important role both in colonization and 
persistence of B. pertussis 12743 in the lungs following aerosol 
challenge of mice. Despite the lower bacterial load, we de­
tected significantly higher concentrations of innate proinflam- 
matory cytokine (Fig. 5) and antigen-specific Thl and Thl7 
cells (Fig. 6) in mice infected with the mutant than in mice 
infected with WT B. pertussis (the experiments shown in Fig. 5 
to 7 correspond to a level of bacterial colonization shown in 
Fig. 8A). This provides indirect evidence that the lower lung 
colonization observed with the mutant bacteria is unlikely to be 
due to exposure to a lower dose of viable bacteria but may 
reflect reduced adherence and a stronger host immune re­
sponse due to the absence of the immune-subversive proper­
ties of the TTSS.
DISCUSSION
This study has demonstrated for the first time that B. per­
tussis expresses a functionally active TTSS, which may be lost 
following prolonged in vitro culture of the bacteria. We have 
identified several substrates of the B. pertussis TTSS and shown 
that the TTSS of B. pertussis is an important virulence factor
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FIG. 5. Enhanced inflammatory cytokine and chemokine induction in the lungs of mice infected with AbscN B. pertussis (BP) 12743. BALB/c 
mice were challenged with an aerosol of WT or ¿sbscN B. pertussis 12743. Cytokine and chemokine concentrations were determined by ELISA on 
lung homogenates from mice 3 h and 3, 7, and 14 days (d) after aerosol challenge and in uninfected control mice. Results are means ± standard 
deviations for four mice per group at each time point. *,  P < 0.05; **,  P < 0.01; ***,  P < 0.001 (isbscN versus WT).
and immunomodulatory apparatus for subverting protective 
immune responses and prolonging survival in the host. It ap­
pears that the TTSS may facilitate colonization and survival of 
B. pertussis by promoting bacterial adherence and by inhibiting 
local innate inflammatory responses and the consequent induc­
tion of antigen-specific Thl, Thl7, and Ab responses that func­
tion to clear the bacteria from the respiratory tract.
The closely related pathogens B. pertussis and B. bronchisep­
tica produce a range of common virulence factors, including 
adhesins and toxins, which function to establish and maintain 
the infection, but have also evolved distinct strategies for sur­
vival in the host. The relatively short-lived and acute severity of 
B. pertussis infection of humans, which favors a high rate of 
host-to-host transmission, contrasts with the relatively asymp­
tomatic and often lifelong persistence of B. bronchiseptica in­
fection in animals. This was thought to be consistent with the 
functional activity of the TTSS in B. bronchiseptica, which sup­
presses DC maturation and migration (32, 33), and the lack of 
TTSS function in B. pertussis Tohama I. However, the present 
study has revealed that clinical isolates of B. pertussis do ex-
press a functionally active TTSS, which plays a role in promot­
ing more efficient bacterial colonization and persistence 
through immunosuppression following respiratory infection of 
mice. We demonstrated significant secretion of Bsp22, a reli­
able marker of a functional TTSS in Bordetella spp. (39), by 15 
of 16 clinical isolates of B. pertussis, in addition to 2 isolates 
obtained from the ATCC, B. pertussis 12743 and 9340, which 
had not undergone extensive laboratory passage. We also dem­
onstrated secretion of two additional Bordetella TTSS sub­
strates, BopN and BopD, by B. pertussis 12743. In contrast, 
secretion of TTSS substrates could not be detected in two 
well-studied laboratory-adapted strains of B. pertussis, Tohama 
I and Wellcome 28. While the TTSS loci are conserved and 
have been shown to be transcribed in B. pertussis Tohama I 
during in vitro growth, it has been suggested that protein trans­
lation is prevented by a posttranscriptional block (22). The 
sequencing of the B. pertussis Tohama I genome revealed ex­
tensive expansion of the insertion sequence element IS-ZA7, 
indicative of large-scale genome rearrangements and thus a 
high level of genome plasticity. Long-term laboratory passage
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FIG. 6. Enhanced antigen-specific IL-17 and IFN-7 production in mice infected with ¿sbscN B. pertussis (BP) 12743. BALB/c mice were 
challenged with an aerosol of WT or ¿sbscN B. pertussis 12743. Spleen cells recovered 14 (A and C) and 21 (B and D) days postchallenge were 
stimulated with sonicated B. pertussis 32743 (Bp), FHA, PT, or medium (Med) only as a control. Supernatants were removed after 3 days, and IL-17 
(A and B) and IFN-7 (C and D) concentrations were determined by ELISA. *, P < 0.05; **, P < 0.01; ***, P < 0.001 (AbscN versus WT).
can lead to significant changes in gene expression and viru­
lence factor production in E. coli and Pseudomonas and Staph­
ylococcus spp. (11). Compared with that in laboratory-cultured 
strains, transcription of genes encoding the TTSS and its ef­
fector proteins was upregulated in a highly adherent P. aerugi­
nosa strain isolated from the lung of a cystic fibrosis patient, 
and this correlated with increased cytotoxicity in vitro and 
enhanced virulence in the respiratory tracts of mice (37). Fur­
thermore, it has been reported that the Yersinia YopT TTSS 
effector protein is not expressed by serotype 03 strains of Y. 
pseudotuberculosis that have been extensively passaged in vitro 
(36). Significant changes in gene transcription by clinical iso­
lates of B. pertussis were reported after as few as 12 laboratory 
passages (2), indicating that B. pertussis, like other bacterial 
species, can alter gene expression when introduced into a new 
environment. It is therefore possible that the absence of a 
functional TTSS in B. pertussis Tohama I and Wellcome 28 is
■■BP 12743
FIG. 7. Enhanced B. pertussis-specific IgG and IgG2a responses in 
mice infected with SbscN B. pertussis (BP) 12743. BALB/c mice were 
challenged with an aerosol of WT or SbscN B. pertussis 12743. Serum 
was recovered from infected mice 28 days postchallenge or from un­
infected control mice and assayed for anti-B. pertussis IgG, IgGl, and 
IgG2a by ELISA. Results are means ± standard deviations for four 
mice per group. *, P < 0.05; **, P < 0.01 (Abs/'N versus WT).
a consequence of long-term laboratory culture in the absence 
of eukaryotic cell contact.
The present study demonstrated that the TTSS of B. bron- 
chiseptica may facilitate bacterial persistence through subver­
sion of bacterial uptake by macrophages, a strategy in the 
pathogenesis of Yersinia spp. (5). We found that B. pertussis 
12743 did not induce cytotoxicity in macrophages, DC, and 
epithelial cells. However, consistent with previous reports (39, 
40), B. bronchiseptica was cytotoxic to a range of cultured cells. 
Although other TTSS effector proteins may also contribute to 
cytotoxicity, it has been demonstrated that BteA, also called 
BopC, is required for the induction of necrotic cell death (19, 
27). Interestingly, BteA/BopC was not detected in secreted 
proteins from B. pertussis 12743. In contrast, we found evi­
dence that the TTSS of B. pertussis facilitates bacterial binding 
to macrophages in vitro. In addition, compared with the WT 
bacteria, the TTSS mutant of B. pertussis YE1Y3 had signifi­
cantly reduced colonization in the lungs 3 h after respiratory 
challenge of mice. Taken together, these data suggest that the 
TTSS of B. pertussis may function as a host adherence factor, as 
has been demonstrated for enteropathogenic E. coli (17).
Significantly, we found evidence that the TTSS facilitates 
persistence of the bacteria in the respiratory tract by subverting 
innate and adaptive immune responses. Protective immunity to 
B. pertussis is mediated through recruitment of neutrophils and 
macrophages to the lungs, local secretion of inflammatory cy­
tokines, and the induction of B. pertussis-specific Thl cells, 
Thl7 cells, and Ab responses (18, 20, 24). IL-12-induced IFN-y 
production by NK cells and Thl cells prevents bacterial dis­
semination from the respiratory tract and activates production 
of opsonizing and complement-fixing IgG2a Abs in the mouse 
(3, 20). IL-23, IL-1, TNF-a, and IL-6 promote the differenti­
ation and expansion of Thl7 cells, and these cells have been 
implicated in inflammatory responses that mediate autoimmu-
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FIG. 8. Ahs/'N B. pertussis 12743 has reduced ability to colonize 
lungs of mice. BALB/c mice were challenged with an aerosol of WT or 
¿sbscN B. pertussis (Bp) 12743, where the challenge inoculum resulted 
in intermediate (A), low (B), or high (C) initial colonization with the 
WT B. pertussis. Groups of four mice were sacrificed 3 h and 3, 7, 14, 
21, and 28 days later, and CFU counts were performed on lung ho­
mogenates. The dashed line represents the limit of detection. **, P < 
0.01; ***,P < 0.001 (STs/'N versus WT). Results are representative of 
three experiments for panel A and one experiment each for panels B 
and C.
nity and also function in the recruitment of neutrophils to the 
site of infection, where they may help contain the pathogen 
until a subsequent clearing IFN-y-producing Thl response can 
be generated (25, 35). We have recently reported that Thl7 
cells have a protective role in vaccine-induced immunity to B. 
pertussis by activating bacterial killing by macrophages (13). In 
the present study we found evidence that deletion of a func­
tional TTSS from B. pertussis 12743 resulted in enhancement 
of local inflammatory responses in the lungs of infected mice. 
Despite the lower bacterial burden in the lungs, mice infected 
with the TTSS mutant had significantly greater local IL-1(3, 
IL-12p40, MI P-1 a, and MIP-2 production. We also observed a 
modest reduction in IL-10 in mice infected with the TTSS 
mutant, and this was significant at day 14. This is consistent 
with the report on B. bronchiseptica where antigen-specific 
IL-10 production in mice infected with the TTSS mutant is 
lower than that in mice infected with WT bacteria (32). In 
contrast, we demonstrated significantly greater B. pertussis­
specific IFN-y, IL-17, and IgG2a responses of mice infected 
with the TTSS mutant than with WT B. pertussis 14 to 28 days 
after B. pertussis challenge. The augmentation of the IL-17 
response to PT in mice infected with the mutant bacteria was 
particularly striking. Although we do not know the precise 
mechanisms, this may reflect enhancement of innate IL-1, 
which together with IL-23 is known to promote the differen­
tiation of Thl7 cells (13). The enhanced cellular immune re­
sponse in mice infected with the TTSS mutant correlated with 
earlier respiratory clearance of TTSS-defective bacteria than 
of WT bacteria. Thus, it appears that the TTSS contributes to 
persistence of B. pertussis by suppressing innate inflammatory 
responses, which not only allows greater bacterial colonization, 
but also delays clearance due to significant suppression of Thl, 
Thl 7, and Ab responses.
Our study provides the first evidence that B. pertussis uses 
the TTSS as a means of colonization and survival in the host 
and may in particular target the innate immune system. Fur­
thermore, we have demonstrated that one of the substrates, 
Bsp22, is secreted in significant quantities by clinical isolates of 
B. pertussis and is immunogenic in animals.
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